These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 29589523)

  • 1. An Update on JAK Inhibitors.
    Musumeci F; Greco C; Giacchello I; Fallacara AL; Ibrahim MM; Grossi G; Brullo C; Schenone S
    Curr Med Chem; 2019; 26(10):1806-1832. PubMed ID: 29589523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
    Dymock BW; See CS
    Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of anticancer activity of nitrogen-containing heterocyclic scaffolds as Janus kinase (JAK) inhibitor: Biological activity, selectivity, and structure-activity relationship.
    Pal R; Matada GSP; Teli G; Saha M; Patel R
    Bioorg Chem; 2024 Nov; 152():107696. PubMed ID: 39167870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor.
    Hamaguchi H; Amano Y; Moritomo A; Shirakami S; Nakajima Y; Nakai K; Nomura N; Ito M; Higashi Y; Inoue T
    Bioorg Med Chem; 2018 Oct; 26(18):4971-4983. PubMed ID: 30145050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors.
    Kim HO
    Arch Pharm Res; 2020 Nov; 43(11):1173-1186. PubMed ID: 33161563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.
    Kettle JG; Åstrand A; Catley M; Grimster NP; Nilsson M; Su Q; Woessner R
    Expert Opin Ther Pat; 2017 Feb; 27(2):145-161. PubMed ID: 27774822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.
    Kettle JG; Åstrand A; Catley M; Grimster NP; Nilsson M; Su Q; Woessner R
    Expert Opin Ther Pat; 2017 Feb; 27(2):127-143. PubMed ID: 27774824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.
    Shen P; Wang Y; Jia X; Xu P; Qin L; Feng X; Li Z; Qiu Z
    Eur J Med Chem; 2022 Sep; 239():114551. PubMed ID: 35749986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current application status and structure-activity relationship of selective and non-selective JAK inhibitors in diseases.
    Li T; Yang X; Zhu J; Liu Y; Jin X; Chen G; Ye L
    Int Immunopharmacol; 2023 Sep; 122():110660. PubMed ID: 37478665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK inhibitor selectivity: new opportunities, better drugs?
    Virtanen A; Spinelli FR; Telliez JB; O'Shea JJ; Silvennoinen O; Gadina M
    Nat Rev Rheumatol; 2024 Oct; 20(10):649-665. PubMed ID: 39251770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
    Hammitzsch A; Lorenz G; Moog P
    Front Immunol; 2020; 11():591176. PubMed ID: 33193430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[ c]pyrrolo[2,3- h][1,6]naphthyridin-5-one (BPN) Series.
    Elsayed MSA; Nielsen JJ; Park S; Park J; Liu Q; Kim CH; Pommier Y; Agama K; Low PS; Cushman M
    J Med Chem; 2018 Dec; 61(23):10440-10462. PubMed ID: 30460842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
    Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
    J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors.
    Nogueira M; Puig L; Torres T
    Drugs; 2020 Mar; 80(4):341-352. PubMed ID: 32020553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitors.
    Xiang J; Wang Y; Wang W; Yu J; Zheng L; Hong Y; Shi L; Zhang C; Chen N; Xu J; Gong X; Zhang Z; Cui H; Zhou Q; Zhang D; Liu Y; Ke Y; Shen J; Xia G; Bai X
    Bioorg Chem; 2023 Nov; 140():106765. PubMed ID: 37582330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
    Norman P
    Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease.
    Hernandez-Rocha C; Vande Casteele N
    Curr Opin Pharmacol; 2020 Dec; 55():99-109. PubMed ID: 33207299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
    He X; Chen X; Zhang H; Xie T; Ye XY
    Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016-present).
    Chen C; Lu D; Sun T; Zhang T
    Expert Opin Ther Pat; 2022 Mar; 32(3):225-242. PubMed ID: 34949146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.